Oslo, Norway, 9 November 2021 - Targovax ASA (OSE: TRVX), a clinical stage
immuno-oncology company developing immune activators to target hard-to-treat
solid tumors, today announces that the posters being presented at the Society
for Immunotherapy of Cancer (SITC) Annual Meeting now are available at the
Company's website.

Both posters are scheduled for presentation 13 November 2021 at the SITC
congress.

Poster      A randomised open-label phase I/II study adding ONCOS-102 to
title:      pemetrexed/cisplatin in patients with unresectable malignant
            pleural mesothelioma - 24-month survival data
E-poster    462
number:
Presenter:  Dr Luis Paz-Ares, Medical Oncology, Hospital Universitario 12
            Octubre, Madrid, Spain

Poster      Consistent pattern of immune activation induced by oncolytic
title:      adenovirus ONCOS-102 across diverse types of solid tumors
E-poster    368
number:
Presenter:  Dr Lone Ottesen, Chief Development Officer, Targovax

The posters are also available on Targovax's
website (https://www.targovax.com/en/oncos-oncolytic-virus-publications-posters
-and-oral-presentations/).

***

For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Email: erik.wiklund@targovax.com

Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: renate.birkeli@targovax.com

Media enquires:
Andreas Tinglum - Corporate Communications (Norway)
Phone: +47 9300 1773
Email: andreas.tinglum@corpcom.no

About Targovax

Activating the patient's immune system to fight cancer
Targovax (OSE:TRVX) is a clinical stage immuno-oncology company developing
immune activators to target hard-to-treat solid tumors. Targovax aims to unlock
greater clinical benefits in cancer patients by deploying its multifunctional
platforms to target key immune regulators and oncogenic drivers. Targovax's
focus is to "activate the patient's immune system to fight cancer", thus
extending and transforming the lives of cancer patients. Targovax's pipeline
aims at different cancer indications, including melanoma, mesothelioma and
colorectal cancer. The company's product candidates are designed to harness the
patient's own immune system to fight the cancer, whilst also delivering a
favorable safety and tolerability profile.

Targovax's lead clinical candidate, ONCOS-102, is a genetically modified
oncolytic adenovirus, which has been engineered to selectively infect cancer
cells and activate the immune system to fight the cancer. On the back of very
encouraging clinical data in several indications, both in monotherapy and in
multiple combinations, the next development steps for ONCOS-102 will be to
further improve responses in melanoma patients resistant to or poorly responsive
to current standard of care.